These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17526091)

  • 21. Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time?
    Perissinotti AJ; Marini BL
    Mycoses; 2019 Mar; 62(3):214-216. PubMed ID: 30474309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT.
    Molina JR; Serrano J; Sánchez-García J; Rodríguez-Villa A; Gómez P; Tallón D; Martín V; Rodríguez G; Rojas R; Martín C; Martínez F; Alvarez MA; Torres A
    Bone Marrow Transplant; 2012 Apr; 47(4):562-7. PubMed ID: 21572466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
    Sung AH; Marcella SW; Xie Y
    J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of primary antifungal prophylaxis in patients with haematological malignancies.
    Pagano L; Caira M
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
    Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
    Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
    Athanasakis K; Petrakis I; Kyriopoulos J
    J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posaconazole: an oral triazole with an extended spectrum of activity.
    Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
    Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
    Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
    BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.
    Upton A; McCune JS; Kirby KA; Leisenring W; McDonald G; Batchelder A; Marr KA
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):760-4. PubMed ID: 17580253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifungal prophylaxis in the haematological patient: a practical approach.
    Vázquez L; Carreras E; Serrano D; Jarque I; Mensa J; Barberán J
    Rev Esp Quimioter; 2012 Dec; 25(4):299-304. PubMed ID: 23303265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posaconazole: new indications. Prevention of invasive mycosis and treatment of oropharyngeal candidiasis: no therapeutic advantage.
    Prescrire Int; 2008 Dec; 17(98):233. PubMed ID: 19422144
    [No Abstract]   [Full Text] [Related]  

  • 32. Retrospective survey on the off-label use of posaconazole in pediatric hematology patients.
    Cesaro S; Milano GM; Aversa F
    Eur J Clin Microbiol Infect Dis; 2011 Apr; 30(4):595-6. PubMed ID: 21120565
    [No Abstract]   [Full Text] [Related]  

  • 33. [The latest data on posaconazole].
    Paugam A
    Med Mal Infect; 2007 Feb; 37(2):71-6. PubMed ID: 17267154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of cross-hepatotoxicity between voriconazole and posaconazole.
    Foo H; Gottlieb T
    Clin Infect Dis; 2007 Sep; 45(6):803-5. PubMed ID: 17712772
    [No Abstract]   [Full Text] [Related]  

  • 35. [Meta-analysis of the efficacy and safety of fluconazole in prophylaxis of fungal infection in very low birth weight infants].
    Zhang JP; Chen C
    Zhonghua Er Ke Za Zhi; 2009 Dec; 47(12):891-7. PubMed ID: 20193139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels.
    Mahmood M; Abu Saleh O; Sohail MR
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167540
    [No Abstract]   [Full Text] [Related]  

  • 37. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.
    Jang SH; Colangelo PM; Gobburu JV
    Clin Pharmacol Ther; 2010 Jul; 88(1):115-9. PubMed ID: 20505665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
    Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
    Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Level of evidence for therapeutic drug monitoring of posaconazole].
    Lefeuvre S; Jelassi ML; Benlmouden A; Berge M; Le Guellec C; Billaud EM;
    Therapie; 2011; 66(2):115-22. PubMed ID: 21635858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients.
    Peterson L; Ostermann J; Rieger H; Ostermann H; Rieger CT
    Mycoses; 2013 Nov; 56(6):651-8. PubMed ID: 23710592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.